

# Is There a Regional Difference in Symptoms Perception Associated with Pre-Menstrual Syndrome? Results from a National Study among Reproductive-Age Women in Brazil

Vivienne Carduz Castilho

Received: 1 January 1970 Accepted: 1 January 1970 Published: 1 January 1970

6 

---

Background: Evaluate the prevalence, intensity and regional distribution of premenstrual syndrome (PMS) symptoms reported by reproductive age Brazilian women. Methods: An observational and retrospective study was conducted analyzing data of women from the five Brazilian regions. Women aged 20 to 49 years who consulted at private healthcare services filled up a self-reported questionnaire about the prevalence and intensity of somatic and psychoemotional pre-menstrual symptoms. Results: A total of 23104 women stated to have premenstrual symptoms, of which 38.91

**Index terms**— premenstrual syndrome, Brazilian women, regional study, premenstrual severity symptoms. Is There a Regional Difference in Symptoms Perception Associated with Pre-Menstrual Syndrome? Results from a National Study among Reproductive-Age Women in Brazil There are several different psycho-emotional and physical symptoms associated with PMS as depression, angry outbursts, irritability, anxiety, confusion, social withdrawal, breast tenderness, abdominal bloating, headache and swelling of extremities [2]. These symptoms are cyclic and recurrent and can change in extent and intensity during different menstrual cycles [2]. According to the World Health Organization, "Premenstrual Tension Syndrome" is characterized by certain environmental, metabolic, or behavioral symptoms that occur during the luteal phase of the menstrual cycle, and lead to cyclic emotional, physical, or behavioral symptoms that interfere with an individual's lifestyle [3]. The American College of Obstetrics and Gynecology and the Royal College of Obstetricians and Gynecologists' criteria describe PMS as any number of psychoemotional or physical symptoms and functional impairment is required [4].

Since PMS is a global problem, it has been studied worldwide to understand its effects on daily life [5,6]. The first global meta-analysis reported the pooled prevalence of PMS at values around 47.8% worldwide, although most of the included studies were heterogeneous, involving several confounding factors within and between studies, and a limited sample size [7]. Some studies suggested that the prevalence of PMS is higher in Latin-American countries when compared to Europe [8].

In Brazil, there are few published studies on the prevalence, symptoms characteristics, and detailed information about the premenstrual syndrome in women of reproductive age. In addition, the correlation with socio-demographic, socioeconomic, and sociocultural conditions of the affected women is not established [9][10][11][12]. However, a study in the Brazilian population showed that when using criteria for the diagnosis of PMS, the prevalence of the syndrome was lower than the self-reported [9]. Therefore, nationwide studies looking at regional differences involving a large sample size among sufferers of PMS are scarce, and new data will contribute to demystifying PMS and help health professionals to assist affected women.

39 This study aimed to evaluate the prevalence, intensity and regional distribution of PMS symptoms reported  
40 by the Brazilian female population and the information generated may help to rethink mechanisms to improve  
41 the health and quality of life of PMS suffering women and offer decision-making tools related to the need for  
42 early and effective treatment of PMS.

## 7 RESULTS

---

43 **1 II.**

44 **2 Methods**

45 **3 a) Study design and sample selection**

46 It was an observational and retrospective study. All data were collected from a database with information stored  
47 by the Market Research Programs (MRP) and anonymized to ensure the data subjects' confidentiality and the  
48 study's security and confidentiality.

49 A self-reported questionnaire was answered by women aged 20 to 49 years from all Brazilian regions: South,  
50 Southeast, North, Northeast, and Midwest, between February 2019 and March 2020. The invitation to participate  
51 was made through an electronic device (cell phone or tablet). As soon as the woman requested access to the  
52 clinic's wireless network, she was invited to participate in the research and received information about the content  
53 and purpose of the research. This study was free from a consent form. The duration of the questionnaire filling  
54 out was around five to ten minutes.

55 Next, the participants were categorized as having PMS or not, according to the ACOG diagnostic criteria [2].  
56 To evaluate functional impairment, the participants were asked how much the PMS symptoms disturbed their  
57 daily life (not at all, a little, or a lot) and those who answered "a lot" were considered as having a functional  
58 impairment.

59 Those who accepted to participate voluntarily were directed to the questionnaire adapted from the PSST  
60 -Premenstrual Symptoms Screening Tool -version validated in Brazil (Annex 1) [13].PSST is a retrospective  
61 questionnaire that can be completed during clinical consultation which is well established for PMS symptoms. It  
62 has demonstrated high sensitivity (79%) for PMS diagnosis and, in addition, identified women who suffer from  
63 severe PMS [14].

64 A 4-point Likert scale was used to measure the intensity of psychoemotional (irritability, anxiety and tension,  
65 decreased interest in routine activities, depression and sadness, overeating, concentration difficulties, emotional  
66 instability) and physical(headache, acne and oily skin, edema, weight gain, breast tenderness, exacerbation of  
67 immunoallergic conditions) symptoms according to intensity (0 = none; 1 = mild; 2 = moderate; 3 = severe).  
68 Also, demographic data of the participants were collected, and they were asked whether they would take oral  
69 contraceptives as a treatment option for PMS.

70 To have representativeness according to regional population, the respondent women were randomly selected  
71 according to the population proportions by region, based on the latest published demographic Census (2010)  
72 ??15]. The study flow chart is represented in Figure 1.

73 The study protocol was submitted to the Research Ethics Committee under the registration number  
74 33794520.1.0000.8098.

75 **4 b) Sample Calculation**

76 To calculate the sample size, an estimation formula was used for a descriptive study with a categorical qualitative  
77 variable [16][17][18]. In this case, the premenstrual syndrome (PMS) estimate was obtained from the literature  
78 [10].The level of significance alpha or type I error was set at 5% (or 95% confidence interval) and the sampling  
79 error at 3% (d=0.03). According to the results, a minimum sample of n=1022 was obtained. The program used  
80 was SAS (Statistical Analysis System), version 9.4 (SAS Institute Inc, 2002-2012, Cary, NC, USA).

81 According to the 2010 Demographic Census data, ??15] the Brazilian female population aged 20 to 49 years  
82 was distributed as follows: 42.4% in the Southeast, 26.9% in the Northeast, 14.1% in the South, 8.9% in the  
83 Midwest and 7.7% in the North region. A specific procedure was used for this selection that randomly shuffles  
84 and chooses lines among those available in each region, using the SAS statistical software.

85 **5 c) Statistical methods**

86 According to the variables under study, the sample characteristics are shown as frequency tables of categorical  
87 variables with absolute (n) and percentage (%) frequency values.

88 Comparisons among regions concerning the response of each question were analyzed using Pearson's Chi-  
89 Square test or Analysis of Variance (ANOVA). If a significant difference was found at 5% in the first test,  
90 multiple comparisons were performed so that each region was compared. Bonferroni's correction test was used  
91 for multiple comparisons.

92 The p-value was considered significant at 0.8%, resulting from the significance level of 5% divided by 6. We used  
93 Poisson Regression to compare regions regarding the number of moderate or severe symptoms, an appropriate  
94 statistical test for numerical data. All analyzes were performed using SAS software version 9.4 and Excel.

95 **6 III.**

96 **7 Results**

97 A total of 56,948 women responded to the initial questionnaire. Of these, 8,990 were aged between 20 and 49 years  
98 and met the diagnostic criteria for PMS (any number of psycho-emotional or physical symptoms with functional

99 impairment). Among them, 5,121 participants agreed to answer a detailed anamnesis about their symptoms,  
100 characterizing the target population of the study.

101 After that, 2,475 respondents were randomized respecting the proportionality of the female population of each  
102 state, according to the 2010 census(Table 1).

103 The mean age of participants was  $30.8 \pm 7.4$  years. Women between 20 and 29 years represented 47.8% of  
104 the sample, corresponding to the larger age group. The participants aged between 40 to 49 years represented  
105 the lowest proportion of respondents (14.4%).The mean age was higher in the southeast region (31.4,  $p=0.0003$ ).  
106 Among the different Brazilian regions, the proportion of respondents in each age group was uniform (Table 2).

107 The profile of the participants who did not accept to respond to the questionnaire was similar to participants  
108 who accepted to respond, regarding the Brazilian regions and age group. Half of the participants in each profile  
109 agreed to answer the questionnaire.

110 By analyzing the total prevalence of symptoms and the distribution of severe physical symptoms, it was  
111 observed no significant differences between the regions of Brazil, except for the lower prevalence of weight gain  
112 in the northeast region (Table 3).

113 Headache was the most prevalent physical symptom (86.2%) in the Brazil average, as well as in the South and  
114 Midwest regions, and 41% of the women with headaches presented the symptom with severe intensity. The second  
115 most prevalent symptom in the Brazil average was acne and oily skin (85.8%), with 32.3% of severe intensity,  
116 followed by edema (85% prevalence, 25.5% with severe intensity). Acne and oily skin were also the most prevalent  
117 symptom in the Southeast and Northeast regions. In the North region, edema was the most prevalent physical  
118 symptom (Table 3).

119 Weight gain was the only physical symptom with a statistically significantly lower prevalence in the northeast  
120 region compared to other regions of the country (Table 3).

121 The least prevalent and severe symptom was an exacerbation of immunoallergic conditions (78.8% and 15.4%)  
122 respectively (Table 3).

123 When focusing on the psychoemotional symptoms, the most prevalent symptom in the country was irritability  
124 (98.5%) with 61.7% of women presenting the symptom in severe intensity. Anxiety and tension were the second  
125 most prevalent psychoemotional symptom in the Brazilian population (98.4%) and 54.2% of the participants  
126 presented it in severe intensity (average). The most prevalence of this symptom was observed in the south  
127 region. Regarding intensity, it was statistically significant in the northeast and southeast regions. In the South  
128 region, both symptoms (irritability / Anxiety and tension) showed the same higher prevalence (99.4%). The  
129 third most prevalent symptom in the country was decreased interest in routine activities (94.5%) and 39% of  
130 women considered it to be of severe intensity (Table ??).

131 Overeating was the only symptom was observed with a statistically significant difference between regions for  
132 prevalence and intensity.

133 On average, 74.3% of women with PMS stated they would take contraceptivesas an option for PMS symptoms  
134 treatment (Table ??).

135 IV.

## 136 8 Discussion

137 Our investigation showed a high prevalence of physical and psychoemotional symptoms in all Brazilian regions,  
138 with the average prevalence of these symptoms in Brazil being 83.6% and 94.2%, respectively.

139 In a study in southern Brazil 1395 women aged 15 to 49 years were evaluated. The main premenstrual  
140 physical symptoms found in this study were abdominal discomfort, headache and breast pain. Among the  
141 psychoemotional symptoms, the most prevalent were irritability, nervousness and fatigue. [9] In our study the  
142 most prevalent physical symptoms were headache (86.2%), acne and oily skin (85.8), and edema (85%) and  
143 the psychoemotional symptoms were irritability (98.5%), anxiety and tension (98.4%) and decreased interest in  
144 routine activities (94.5%).

145 In a multicenter Brazilian study that aimed to describe the perspectives and attitudes of Brazilian women  
146 toward premenstrual syndrome,1053 women, separated by regions, between 18 and 40 years, lived in 6 Brazilian  
147 cities, 1 in each geographic region of the country and the Federal District were interviewed [10]. Results  
148 showed that most women (78.1%) stated that PMS is related to emotional symptoms, and 24.3% said that  
149 it is related to physical symptoms [10]. The emotional symptoms most frequently mentioned by the participants  
150 were nervousness/anxiety, irritability/anger/ aggressiveness and mood swings/crying, whereas the most common  
151 physical symptoms were headache, cramps and breast pain, swelling, and tenderness [10]. On the other hand,  
152 in our investigation we observed that irritability and anxiety/tension were the most prevalent psychoemotional  
153 symptoms.

154 When evaluating the prevalence of symptoms with severe intensity, our study showed a higher prevalence of  
155 psychoemotional symptoms over physical symptoms, reaching 60% for irritability versus 40% for headache, which  
156 was the most severe physical symptom.

157 In a study across several countries, including Brazil, with a total of 7226 women (400-500 women from each  
158 country) aged 15-49, it has been reported a higher frequency of physical symptoms, as assessed by severity  
159 and number of menstrual cycles affected [6]. In this global study, Brazil was characterized by the second-largest  
160 values of severity and duration of symptoms, staying only behind the UK. The high prevalence of severe symptoms

161 observed in our study corroborates these findings. However, when evaluating the global population, among the 5  
162 most prevalent symptoms, 4 were physical [6]. In our study, psychoemotional symptoms were a higher prevalence  
163 and severity. It is important to highlight that these data were collected before the pandemic of COVID-19, so  
164 these results were not influenced by the psychological effects seen during the pandemic. We continue to collect  
165 data during the pandemic, and it will be interesting to compare this issue.

166 The lower severity of overeating in the northeast region may be related to the lower severity of anxiety and  
167 tension during the premenstrual period.

168 Previously studies showed that among Brazilian women, 52.3% stated that physicians prescribed hormones as  
169 a strategy for dealing with premenstrual syndrome, [10] and PMS symptoms severity was inversely associated  
170 with oral contraceptive use (emotional symptoms) and better-perceived health (physical symptoms) [19].In our  
171 investigation, among respondents who met the diagnostic criteria for PMS (n=2.475), 74.3% would take oral  
172 hormonal contraceptives as a treatment option for PMS. This is an important finding since the combined oral  
173 contraception for women of reproductive age is one of the effective options used for the treatment of PMS, mainly  
174 for women who seek contraception counseling. [20] The strength of this study includes the use of a questionnaire  
175 validated in Brazil that is commonly used for population studies, the large number of women included, and the  
176 national scope of the study. In addition, the participating women included in our study were selected in a private  
177 healthcare system to minimize bias-related the socioeconomic status of participants. A limitation of this study  
178 is that data such as education and family income of the participants were not collected.


179 V.

## 180 9 Conclusion

181 Psychoemotional symptoms are more frequent and severe than somatic symptoms. There were a lot of similarities  
182 in women's experiences of these symptoms across Brazilian regions. Symptoms had a frequency and intensity  
183 regardless of the region, which makes many women states that would be willing to take a contraceptive that  
184 reduces TPM symptoms. It is important for healthcare professionals, to make screening symptoms associated  
185 with SPM during contraception counseling to choose the most proper option.

## 186 10 List of abbreviations

187 Premenstrual syndrome; MRP: Market Research Programs; PSST: Premenstrual Symptoms Screening Tool <sup>1</sup>



1

Year 2022

6

Volume XXII

Issue III

Version I

D D D D ) E

(

Medical

Research

Global Journal of	Region	State	Distrito	Target Population	91 (35.3%)	94 (36.4%)	54 (20.9%)	Rando
	Mid-west	Federal	Goiás					
			Mato Grosso					
			Mato Grosso do Sul	19	(7.4%)			17
			Total	258	(100%)			221
North		Amazonas		114	(57.6%)			108
		Pará		41	(20.7%)			40
		Tocantins		43	(21.7%)			42
		Total		198	(100%)			190
© 2022								
Global								
Jour-								
nals								

Figure 2: Table 1 :

2

Region of Brazil	(n=221)	Midwest	North (n=190)	Northeast (n=666)	South (n=348)
Profile -n (%)					
20 to 29 years	107 (48.4)	106 (55.8)	341 (51.2)	168 (48.3)	
30 to 39 years	80 (36.2)	63 (33.2)	247 (37.1)	128 (36.8)	
40 to 49 years	34 (15.4)	21 (11.1)	78 (11.7)	52 (14.9)	
Total of participants	221 (100%)	190 (100%)	666 (100%)	348 (100%)	
Mean (S.D.)	30.7 (7.4)	29.8 (7.2)	30.2 (7.3)	30.5 (7.5)	
Median (Min -Max)	30 (20 -49)	28 (20 -49)	29 (20 -49)	30 (20 -49)	
p (Anova Region * Age) =	p = 0.9641	p = 0.0645	p = 0.0222	p = 0.4165	
0.0043					

Multiple comparisons: each region with the rest of country (?) for Bonferroni correction = 0.008)

\* numbers means statistical significance compared with the others.

Figure 3: Table 2 :

---

### 3

Region of Brazil	Midwest North (n=221) (n=190)
Physical symptoms (%)	
Headache	Prevalence 86.8
	Severe 43.2
	intensity
Acne and oily skin	Prevalence 85.1
	Severe 33.0
	intensity
Edema	Prevalence 84.2
	Severe 23.1
	intensity
Weight gain *	Prevalence 84.6
	Severe 32.6
	intensity

Year Prevalence Severe intensity Prevalence Severe intensity \* numbers means statistical significance compared to 2022

8

Figure 4: Table 3 :



188 .1 Acknowledgments

189 The authors would like to thank all participants in this research.

190 .2 Authors contribution

191 Adriana O. Pedro contributed to the design, writing and revision of the manuscript; Samantha B. O. Silva  
192 contributed to the design, data analysis and wrote the manuscript; Maura G. Lapa contributed to data  
193 analysis; Juliana D. P. Brandao contributed to data analysis and wrote the manuscript and Vivienne C. Castilho  
194 contributed to the design and revision of the manuscript.

195 All authors discussed the results and contributed to the final manuscript.

196 .3 Funding

197 This research was supported by Libbs Farmacéutica Ltda (Brazil) provided funding and material support for  
198 this research (protocol number LB1105).

199 .4 Availability of data and materials

200 The data generated during and/or analyzed during the current study are available from the corresponding author  
201 on reasonable request.

202 .5 Declarations

203 All procedures performed in this research were in accordance with the ethical standards and approved by Research  
204 Ethics Committee in all participating sites and was conducted following the ethical standards outlined in the  
205 Helsinki Declaration ??1983).

206 .6 Competing interests

207 Adriana O. Pedro has served on advisory boards or has been a consultant for Libbs Farmacéutica, Abbott, Achè,  
208 Amgen, EMS, Eurofarma, Grumenthal, Mantecorp-Farmasa, and Sanofi. She has also served on the speaker's  
209 bureau for Libbs Farmacéutica, Abbott, Achè, Amgen, EMS, Eurofarma, Grumenthal, Mantecorp-Farmasa, and  
210 Sanofi-Aventis. Samantha B. de Oliveira, Maura G. Lapa, Juliana D. P. Brandao and Vivienne C. Castilho are  
211 employed at Libbs Farmacéutica, Medical Affairs Division.

212 [Fonseca et al. ()] , J S Fonseca , G A Martins , *Curso De Estatística* . 1994. São Paulo: Atlas. (5th edition)

213 [Silva et al. ()] , C M Silva , D P Gigante , M L Carret , A G Fassa . *Rev Saude Publica* 2006. 40 (1) p. .  
214 (Population study of premenstrual syndrome)

215 [Bahamondes et al.] L Bahamondes , S Córdova-Egüez , J E Pons , L Shulman . *Perspectives on Premenstrual  
216 Syndrome/Premenstrual Dysphoric Disorder*,

217 [Hulley et al. ()] 'Designing Clinical Research'. S Hulley , S Cummings , W Browner , D Grady , T Newman .  
218 *Designing Clinical Research* 2007. Williams & Wilkins. (3rd ed)

219 [Disease Management Health Outcomes ()] *Disease Management & Health Outcomes*, 2007. 15 p. .

220 [Ashraf et al. ()] 'Epidemiology of Premenstrual Syndrome (PMS)-A Systematic Review and Meta-Analysis  
221 Study'. D-M Ashraf , S Kourosh , D Ali , K Sattar . *J Clin Diagn Res* 2014. 8 (2) p. .

222 [Dennerstein et al. ()] 'Global study of women's experiences of premenstrual symptoms and their effects on daily  
223 life'. L Dennerstein , P Lehert , K Heinemann . *Menopause Int* 2011. 17 (3) p. .

224 [International Classification of Diseases 11th Revision] *International Classification of Diseases 11th Revision*,  
225 <<https://icd.who.int/en>> (Accessed 18 March 2022)

226 [Di Scalea and Pearlstein ()] 'Premenstrual Dysphoric Disorder'. Lanza Di Scalea , T Pearlstein , T . *Med Clin  
227 North Am* 2019. 103 (4) p. .

228 [Dennerstein et al. ()] 'Premenstrual symptoms -severity, duration and typology: an international cross-sectional  
229 study'. L Dennerstein , P Lehert , T C Bäckström , K Heinemann . *Menopause Int* 2009. 15 (3) p. .

230 [Acog Practice Bulletin ()] 'Premenstrual syndrome'. Acog Practice Bulletin . *Obstet Gynecol* 2000. 95 (15) p. .

231 [Petta et al. ()] 'Premenstrual syndrome as reported by Brazilian women'. C A Petta , M J Osis , K S De Pádua  
232 , L Bahamondes , M Y Makuch . *Int J Gynaecol Obstet* 2010. 108 (1) p. .

233 [Henz et al. ()] 'Premenstrual Syndrome Diagnosis: A Comparative Study between the Daily Record of Severity  
234 of Problems (DRSP) and the Premenstrual Symptoms Screening Tool (PSST)'. A Henz , C F Ferreira , C L  
235 Oderich , C W Gallon , Jrs Castro , M Conzatti , Mpa Fleck , Mco Wender . *Rev Bras Ginecol Obstet* 2018.  
236 40 (1) p. .

237 [Rezende et al.] 'Prevalence of Premenstrual Syndrome and Associated Factors Among Academics of a University  
238 in Midwest Brazil'. Apr Rezende , F R Alvarenga , M Ramos , D L Franken , J S Dias Da Costa , M P Pattussi  
239 , Vmv Paniz . *Rev Bras Ginecol Obstet* 2022 (2) p. .

## 10 LIST OF ABBREVIATIONS

---

240 [Victor et al.] 'Quality of Life among University Students with Premenstrual Syndrome'. F F Victor , A I Souza  
241 , Cdt Barreiros , Jln Barros , F Silva , A Ferreira . *Rev Bras Ginecol Obstet* 2019 (5) p. .

242 [Sternfeld et al. ()] 'Severity of premenstrual symptoms in a health maintenance organization population'. B  
243 Sternfeld , R Swindle , A Chawla , S Long , S Kennedy . *Obstet Gynecol* 2002. 99 (6) p. .

244 [Cohen ()] *Statistical Power Analysis for the Behavioral Sciences*, J Cohen . 2022. New York: Routledge.

245 [Freeman ()] 'Therapeutic management of premenstrual syndrome'. E W Freeman . *Expert Opin Pharmacother*  
246 2010. 11 (17) p. 2022. (5 Year)

247 [O'brien et al. ()] 'Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual  
248 disorders: the ISPMd Montreal consensus'. P M O'brien , T Bäckström , C Brown , L Dennerstein , J  
249 Endicott , C N Epperson , E Eriksson , E Freeman , U Halbreich , K M Ismail . *Arch Womens Ment Health*  
250 2011. 14 (1) p. .

251 [Câmara et al. ()] 'Validation of the Brazilian Portuguese version of the Premenstrual Symptoms Screening Tool  
252 (PSST) and association of PSST scores with health-related quality of life'. R A Câmara , C A Köhler , B N  
253 Frey , T N Hyphantis , A F Carvalho . *Braz J Psychiatry* 2017. 39 (2) p. .